Abstract
Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11+). An additional 11 patients had stabilisation of disease. The patients received a median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) l-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Biran H., Sulkes A., Biran S. 5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage. Oncology. 1989;46(2):83–87. doi: 10.1159/000226690. [DOI] [PubMed] [Google Scholar]
- Bissery M. C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991 Sep 15;51(18):4845–4852. [PubMed] [Google Scholar]
- Burris H., Irvin R., Kuhn J., Kalter S., Smith L., Shaffer D., Fields S., Weiss G., Eckardt J., Rodriguez G. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993 May;11(5):950–958. doi: 10.1200/JCO.1993.11.5.950. [DOI] [PubMed] [Google Scholar]
- Guéritte-Voegelein F., Guénard D., Lavelle F., Le Goff M. T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991 Mar;34(3):992–998. doi: 10.1021/jm00107a017. [DOI] [PubMed] [Google Scholar]
- Kelsen D. Chemotherapy of gastric cancer: a review. Isr J Med Sci. 1988 Sep-Oct;24(9-10):557–561. [PubMed] [Google Scholar]
- MacDonald J. S., Schein P. S., Woolley P. V., Smythe T., Ueno W., Hoth D., Smith F., Boiron M., Gisselbrecht C., Brunet R. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980 Oct;93(4):533–536. doi: 10.7326/0003-4819-93-4-533. [DOI] [PubMed] [Google Scholar]
- Riggi M., Ruffie P., Voisin S., Monnet I., de Cremoux H., Saltiel J. C., Martin M., Vergne L., Huet J., Cvitkovic E. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques). Eur J Cancer. 1991;27(10):1238–1242. doi: 10.1016/0277-5379(91)90089-v. [DOI] [PubMed] [Google Scholar]
- Silverberg E. Cancer statistics, 1985. CA Cancer J Clin. 1985 Jan-Feb;35(1):19–35. doi: 10.3322/canjclin.35.1.19. [DOI] [PubMed] [Google Scholar]
- Taal B. G., ten Bokkel Huinink W. W., Franklin H., Rodenhuis S. EAP in advanced gastric cancer. J Clin Oncol. 1990 May;8(5):939–941. doi: 10.1200/JCO.1990.8.5.939. [DOI] [PubMed] [Google Scholar]
- Wils J., Bleiberg H., Dalesio O., Blijham G., Mulder N., Planting A., Splinter T., Duez N. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol. 1986 Dec;4(12):1799–1803. doi: 10.1200/JCO.1986.4.12.1799. [DOI] [PubMed] [Google Scholar]